AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03330600 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aquatic physicotherapy
Description: Aquatic physiotherapy will be performed in a bathtub with water heated to a temperature around 37º C and environment with adequate temperature and luminosity. Kinesiotherapy will begin with smooth sliding movements in the aquatic environment, still in flexor restraint, allowing the child to adapt to the temperature of the new environment; joint mobilizations will be initiated on the shoulders and hips followed by stretching of the accessory muscles of the breath, spine erector, flexor and extensors of shoulder, elbow, hip, knee and ankle. The sessions will last 10 minutes and may be interrupted if the child shows signs of discomfort such as cyanosis, increased respiratory rate, bronchoaspiration or does not adapt to the environment, ie, remain crying for more than 5 minutes.
Study NCT03330600 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: aquatic physicotherapy
Description: Aquatic physiotherapy will be performed in a bathtub with water heated to a temperature around 37º C and environment with adequate temperature and luminosity. Kinesiotherapy will begin with smooth sliding movements in the aquatic environment, still in flexor restraint, allowing the child to adapt to the temperature of the new environment; joint mobilizations will be initiated on the shoulders and hips followed by stretching of the accessory muscles of the breath, spine erector, flexor and extensors of shoulder, elbow, hip, knee and ankle. The sessions will last 10 minutes and may be interrupted if the child shows signs of discomfort such as cyanosis, increased respiratory rate, bronchoaspiration or does not adapt to the environment, ie, remain crying for more than 5 minutes.
Study NCT03330600 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: immersion
Description: The immersion will be performed in a bathtub with water heated to a temperature around 37º C and environment with adequate temperature and luminosity. The therapy will begin with smooth sliding movements in the aquatic environment, still in flexor restraint, allowing the child to adapt to the temperature of the new environment. The sessions will last 10 minutes and may be interrupted if the child shows signs of discomfort such as cyanosis, increased respiratory rate, bronchoaspiration or does not adapt to the environment, ie, remain crying for more than 5 minutes.
Study NCT03330600 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: immersion
Description: The immersion will be performed in a bathtub with water heated to a temperature around 37º C and environment with adequate temperature and luminosity. The therapy will begin with smooth sliding movements in the aquatic environment, still in flexor restraint, allowing the child to adapt to the temperature of the new environment. The sessions will last 10 minutes and may be interrupted if the child shows signs of discomfort such as cyanosis, increased respiratory rate, bronchoaspiration or does not adapt to the environment, ie, remain crying for more than 5 minutes.
Study NCT00799500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening
Description: Weekly vaginal pH
Study NCT04291976 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Back-to-back high-definition white light endoscopy
Description: Using HD white light, the entire colon is examined for dysplasia and other abnormalities after the caecum is reached, with a second segmental inspection after the first examination in the same session.The colonoscope has a high-definition camera and processor. All images are displayed on a high definition monitor for optimal resolution.
Study NCT04291976 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: single-pass high-definition white light endoscopy
Description: Using HD white light, the entire colon is examined for dysplasia and other abnormalities after the caecum is reached. The colonoscope has a high-definition camera and processor. All images are displayed on a high definition monitor for optimal resolution.
Study NCT04291976 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chromoendoscopy
Description: After introduction of the endoscope into the colon a dye (methylene blue or indigo carmine) will be sprayed through a catheter positioned into the biopsy channel. Per segment, the entire colon is dyed, inspected, and lesions are removed. Equipment is similar to the other two interventions.
Study NCT01444313 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: narafilcon A contact lens
Description: Soft contact lenses with UV protection
Study NCT01444313 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: nelfilcon A soft contact lenses
Description: Soft contact lenses without UV protection
Study NCT03608891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer guided patient specific 3D titanium plate
Description: CBCT or CT scan will be done preoperatively and dicom files will be imported to mimics software to design and print the patient specific 3D titanium plate.
Study NCT03608891 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional titanium miniplates
Description: In this group two miniplates of titanium Mini-System 2.0 mm will be used. The plate has profile height 1.0 mm whereas the screw length varies according to the site of the plate. According to Champy osteosynthesis lines for fixation of the posterior mandibular fracture ,the first plate will be placed at the inferior border from the buccal side, using bicortical screws engaging the buccal and lingual cortices to achieve rigid fixation, while the second plate will be placed at about 5mm superior to the inferior plate in the subapical region, using monocortical screws engaging only the buccal cortex to avoid injuring the teeth roots.
Study NCT01273389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 136
Description: Type=exact number, unit=mg/kg, number=10, form=solution for injection, route=intravenous. CNTO 136 is administered once every 4 weeks from Week 0 to Week 24.
Study NCT01273389 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form=solution for injection, route=intravenous. Placebo is administered once every 4 weeks from Week 0 to Week 24.
Study NCT03568812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rillus®
Description: Eligible subjects will be divided into 2 groups randomly (Rillus® or placebo). The colour, smell, flavour, and size of the chewing tablet are the same between active and placebo drugs. Subjects will consume the tablet once daily at night for 12 weeks.
Study NCT03568812 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible subjects will be divided into 2 groups randomly (Rillus® or placebo). The colour, smell, flavour, and size of the chewing tablet are the same between active and placebo drugs. Subjects will consume the tablet once daily at night for 12 weeks.
Study NCT01014702 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LensAR Laser System
Description: Use of laser for capsulotomy and lens fragmentation
Study NCT01014702 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional phacoemulsification
Description: Use of standard techniques for capsulotomy and lens fragmentation
Study NCT01922245 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soterix 1x1 tDCS
Description: Anodal and sham tDCS will be administered. All of the participants will also receive behavioral speech-language therapy.
Study NCT03602261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcifediol Oral Capsule
Description: Capsule, weekly
Study NCT03602261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Capsule, weekly
Study NCT00801853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aerovant
Description: Aerovant 1mg bid (dry powder)
Study NCT00801853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aerovant
Description: Aerovant 3mg bid (dry powder)
Study NCT00801853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aerovant
Description: Aerovant 10mg bid (dry powder)
Study NCT00801853 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo control (dry powder)
Study NCT03852914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate 2%
Description: Each patient will receive a single injection of SH 2% and will be followed for 6 months. At 6 months follow up visit patients could be offered a second injection whenever and when they comply with the criteria established for re-treatment and will be followed for additional 6 months.
Study NCT00433446 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNTO 328
Study NCT03744130 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced Ultrasound
Description: 1. administration of drotaverine hydrochloride (No-Spa ®) to reduse excessive peristaltic movement~2. visualization of the previously chosen affected bowel segment with the use of DCE-US (Dynamic Contrast-Enhanced Ultrasound) technology~3. administration of 2.4 ml SonoVue® intravenously with a bolus injection through a peripheric venous line (left antecubital vein), followed by a 10ml 0.9% Natrium Chloride bolus~4. the video-loop is acquired during contrast agent administration and wash-out (preferable loop duration - 3 min)~5. the original DICOM loop is sent to a work station
Study NCT01640990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: 30mins run-in period
Study NCT01640990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW328267X (total dose of 12mcg)
Description: 8 mcg/h for 1.5 hours (total dose of 12mcg)
Study NCT01640990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW328267X (total dose of 40mcg)
Description: 10 mcg/h for 4 hours (total dose of 40 mcg)
Study NCT02310906 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SRP-4053 placebo-matching solution for IV infusion.
Study NCT02310906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRP-4053
Description: SRP-4053 (golodirsen) solution for IV infusion.
Study NCT00349726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo lower volume
Description: 60 mg/kg (1.2ml/kg) of glucose 5% given intravenously over 20 minutes.
Study NCT00349726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo higher volume
Description: 120 mg/kg (2.4ml/kg) of glucose 5% given intravenously over 20 minutes.
Study NCT02293356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab Injection
Description: patients receive nimotuzumab injection for 200mg/w,intravenous infusion over 60 minutes.Doctor adjust the dosage of nimotuzumab and choose other treatment options according to the actual situation of patients.
Study NCT03141268 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lactulose breath test
Description: Lactulose 0.67 mg/mL, dose 15 mL (10 grams). No contaminants of lactose. Pharmacy quality.
Study NCT02095756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 755nm Alexandrite Laser and Lytera Skin Brightening System (Non-Hydroquinone Topical Therapy)
Study NCT02095756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lytera Skin Brightening System (Non-hydroquinone topical therapy)
Study NCT04295200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling with electrical stimulation
Description: Paravertebral dry needling to L3, 4, 5 multifidi. Electrical stimulation will be applied through the needles for up to 10 minutes total or to the participant's tolerance.
Study NCT01996891 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Anti-Inflammatory Diet
Description: The anti-inflammatory diet will focus on reducing glycemic load, and increasing fiber, fruits, vegetables, legumes and food-based omega-3 fatty acid content.
Study NCT00240539 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: A blood sample will be taken yearly at each long-term follow-up time point (i.e. Year 16 through Year 20) after the first dose of Engerix-B™ vaccine.
Study NCT03718702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ePain
Description: Electronic pain management programme (ePain)
Study NCT03152344 — intervention group
Intervention type: PROCEDURE
Intervention: Timed Up and Go
Description: It's a functional test evaluating the time to rise from a chair, walk 3 meters, turn around, walk back to the chair and sit down (abnormal cut-off value >12 seconds).
Study NCT03219931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium breve BR03 and Bifidobacterium breve B632
Description: This is the active product containing 108 viable cells/strain
Study NCT03219931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: This is the placebo product containing a similar product without bifidobacterium inside.
Study NCT01007747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geranium oil
Description: Daily topical application over neuropathic pain
Study NCT03185013 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VGX-3100
Description: 1 mL VGX-3100 will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.
Study NCT03185013 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mL of Placebo will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.
Study NCT03185013 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Electroporation (EP)
Description: Intramuscular injection followed by EP with the CELLECTRA™ 5PSP device.
Study NCT03185013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroporation (EP)
Description: Intramuscular injection followed by EP with the CELLECTRA™ 5PSP device.
Study NCT01829087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Study NCT01829087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04453098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3-week residential program based on a tryptic (diet,
Description: 3-week residential program based on a tryptic (diet, exercise, education). The three weeks intervention was followed by a 1-year at-home follow-up.~In the original protocol, participants were involved in a 3-week residential program based on a tryptic (diet, exercise, education).
Study NCT02310282 — intervention group
Intervention type: DEVICE
Intervention: Telemedicine
Description: In-hospital telemedicine
Study NCT00650442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Transdermal System Placebo - Alternate Adhesive
Description: single application
Study NCT00650442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Estradiol Transdermal System Placebo - Current Adhesive
Description: single application
Study NCT03394755 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thrombosomes
Description: Freeze-dried platelets
Study NCT00073021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asacol 800 mg (mesalamine)
Description: tablets, 4.8 g/day for 6 weeks, 2 - 800 mg Asacol tablets and 2 placebo tablets 3 times daily
Study NCT00073021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asacol 400 mg (mesalamine)
Description: tablets, 2.4 g/day for 6 weeks, 2 - 400 mg Asacol tablets and 2 placebo tablets 3 times daily
Study NCT03819621 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRISS Medical Technologies mediGrid app
Description: IRISS mediGrid is standalone software, loaded on a mobile electronic platform, which is intended to record and document ophthalmic and other bodily characteristics and to aid in the diagnosis of abnormalities.
Study NCT01398943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin (BH4)
Description: single dose = 5 mg/kg
Study NCT01398943 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant Cocktail
Description: 1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid
Study NCT01414049 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: On-pump CABG
Description: Use of cardiopulmonary bypass (CPB) with cardioplegic arrest: on-pump CABG.
Study NCT01414049 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Description: CABG performed without the use of cardiopulmonary bypass (CPB) with cardioplegic arrest, surgery performed with the beating heart.
Study NCT01121341 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vein harvesting
Description: Endoscopic versus conventional vein harvesting
Study NCT01121341 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vein harvesting
Description: Endoscopic versus conventional vein harvesting
Study NCT03983174 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drainage seton with flap
Description: Seton is placed around the external sphincter then mucosal advancement flap will be constructed
Study NCT03983174 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EAS sparing seton
Description: Rerouting of the seton around the internal sphincter only sparing the external sphincter
Study NCT03251274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: machine bathing
Description: machine bathing 20-min duration at evening
Study NCT03251274 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional bathing
Description: traditional bathing
Study NCT01718470 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube
Description: Hemodynamic variables were recorded at 8 moments: baseline, in the operating room one minute before anesthetic induction; 5 minutes after the end of surgery before awakening (ETT group) and 1, 5, 10, 15, 30 and 60 min after extubation . The last blood pressure and heart rate measurements were taken in the postoperative recovery room.
Study NCT00935337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Bridging Program
Description: Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
Study NCT00935337 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene
Description: treatment as usual
Study NCT00050583 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Ten Weekly Sessions of Manualized CBT
Study NCT00050583 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: Cognitive Behavioral Therapy
Study NCT02098304 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Calcivis Caries Activity Imaging System
Description: Teeth imaged with the Calcivis Caries Activity Imaging System
Study NCT00692003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide
Description: 25-400 mg capsules orally once daily in the evening.~Maximum study duration of 28 weeks comprising:~Baseline Period (Week-8/-4 to Week 0) no treatment~Titration Period (Week 0 to Week 4) \<12 years old: 1 mg/kg; >= 12 years old: 50 mg daily titrated weekly until a dose of 5 mg/kg or 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) dose from Week 4 to be maintained (4 mg/kg or 200 mg in the event of dose limiting adverse events)~Down Titration Period (4 weeks)
Study NCT00692003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 25-400 mg Zonisamide Placebo capsules orally once daily in the evening.~Maximum study duration of 28 weeks comprising:~Baseline Period (Week-8/-4 to Week 0) no treatment~Titration Period (Week 0 to Week 4) \<12 years old: 1 mg/kg Zonisamide Placebo; >= 12 years old: 50 mg Zonisamide Placebo capsules daily titrated weekly until a dose of 5 mg/kg or 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) dose from Week 4 to be maintained (4 mg/kg or 200 mg in the event of dose limiting adverse events)~Down Titration Period (4 weeks)
Study NCT00771173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenazopyridine HCl
Description: Phenazopyrdine HCl 200 mg q8h x 24
Study NCT04072653 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLNB is spared
Description: SLNB is spared in patients with negative preoperative axillary assessment(including LymphPET and other imaging examinations)
Study NCT01535287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Active study agent: Dexmedetomidine at 1 microgram/kilogram Intramuscular (IM) Placebo study agent: Same volume as the study drug of placebo (normal saline).~All blinding, labeling, preparation, storage of agents done by the pharmacist. The drug will be administered into the deltoid muscle by using a TB syringe attached to a 3/4 inch length and 25 Gauge width needle by anesthesia provider after the induction of general anesthesia by the anesthesia provider.
Study NCT01535287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: Active study agent: Dexmedetomidine at 1 microgram/kilogram Intramuscular (IM) Placebo study agent: Same volume as the study drug of placebo (normal saline).~All blinding, labeling, preparation, storage of agents done by the pharmacist. The drug will be administered into the deltoid muscle by using a TB syringe attached to a 3/4 inch length and 25 Gauge width needle by anesthesia provider after the induction of general anesthesia by the anesthesia provider.